NCT07134127View on ClinicalTrials.gov

A Study of IBI3032 in Chinese Healthy Subjects

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy
Interventions
DRUG

placebo

Placebo (without active ingredients) (cohort1, 2,4) Method of administration: oral, fasted administration. Placebo (without active ingredients) (cohort3) Method of administration: oral, administration after meal.

DRUG

IBI3032

IBI3032: (cohort1, 2,4) Method of administration: oral, fasted administration. IBI3032: (cohort3) Method of administration: oral, administration after meal.

Trial Locations (1)

230000

The Frist Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Innovent Biologics Technology Limited (Shanghai R&D Center)

INDUSTRY